TB-403
As of the edition of 20 October 2026, TB-403 is a drug: went quiet in 2020; acts on PGF.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2020
- Kind
- Unknown
- Registered trials
- 7, 0 stopped early
- Disease areas
- Cancer; Digestive system; Eye; Heart and blood vessels; Hormones; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
5 companies on route A because of this drug.
Companies on route A for this drug
In the product5 companies are on route A because of TB-403.
See the 5 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PGF | Placenta growth factor | P49763 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| BioInvent | Lead sponsor of trials | 2008 to now |
| Roche | Lead sponsor of trials | 2010 to now |
| Oncurious | Lead sponsor of trials | 2016 to now |
| Oxurion | Lead sponsor of trials | 2018 to now |
| ThromboGenics | Lead sponsor of trials | 2018 to now |